On day +3, CRS turned into grade 2 (persistent fever, hypotension partially responsive to fluid hydration, oxygen support with low-flow nasal cannula), with increase in C-reactive Protein (CRP) levels (Figure 1A), and tocilizumab was started (8 mg/kg/tid intravenous (IV), for 24 hours). Here, CRP is linked to congenital rubella syndrome.